Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.98 Insider Own4.05% Shs Outstand13.93M Perf Week3.91%
Market Cap62.96M Forward P/E- EPS next Y-3.92 Insider Trans0.00% Shs Float12.80M Perf Month-12.40%
Income-39.80M PEG- EPS next Q-1.10 Inst Own47.80% Short Float4.17% Perf Quarter-16.30%
Sales- P/S- EPS this Y66.30% Inst Trans1.25% Short Ratio5.39 Perf Half Y-48.05%
Book/sh5.02 P/B0.90 EPS next Y-1.30% ROA-44.60% Target Price4.00 Perf Year-61.20%
Cash/sh6.09 P/C0.74 EPS next 5Y5.60% ROE-58.40% 52W Range3.34 - 12.45 Perf YTD-55.90%
Dividend- P/FCF- EPS past 5Y20.20% ROI- 52W High-63.69% Beta2.42
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low35.33% ATR0.34
Employees72 Current Ratio4.00 Sales Q/Q- Oper. Margin- RSI (14)48.86 Volatility5.95% 9.13%
OptionableYes Debt/Eq0.22 EPS Q/Q-129.40% Profit Margin- Rel Volume0.24 Prev Close4.56
ShortableYes LT Debt/Eq0.22 EarningsNov 07 BMO Payout- Avg Volume99.04K Price4.52
Recom3.30 SMA206.64% SMA50-7.01% SMA200-37.10% Volume23,570 Change-0.88%
Oct-07-16Downgrade JP Morgan Overweight → Neutral
May-27-16Initiated Robert W. Baird Neutral $8
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Nov-13-18 01:20AM  Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 10:31AM  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3 Zacks
08:45AM  Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-08-18 10:17AM  Merrimack to shelve lead cancer drug, lay off most of workforce American City Business Journals
Nov-07-18 06:45AM  Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review PR Newswire +9.20%
Nov-06-18 01:44PM  Merrimack Pharmaceuticals Q3 Earnings Preview Benzinga
Nov-05-18 07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Oct-31-18 04:05PM  Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call PR Newswire
Oct-24-18 11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks -6.67%
Oct-19-18 10:48AM  Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials Benzinga -22.29%
07:46AM  Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated MarketWatch
06:00AM  Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility PR Newswire
Oct-16-18 07:30AM  Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack What Drives Growth in Today's Competitive Landscape GlobeNewswire
Oct-11-18 05:16PM  Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts Zacks
Sep-20-18 07:00AM  Merrimack Receives $5 Million Milestone Payment from Shire PR Newswire
Sep-06-18 10:35AM  Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue? Zacks -5.75%
06:50AM  Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC) PR Newswire
Sep-05-18 12:06PM  Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Sep-04-18 10:07AM  Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank Zacks
Aug-16-18 08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX New Research Emphasizes Economic Growth GlobeNewswire
Aug-08-18 10:20AM  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2 Zacks
Aug-07-18 08:18AM  Merrimack (MACK) Reports Wider-than-Expected Q2 Loss Zacks
06:30AM  Merrimack Reports Second Quarter 2018 Financial Results PR Newswire
06:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 12:09PM  Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings? Zacks
Jul-31-18 04:10PM  Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call PR Newswire
Jul-10-18 04:55PM  Ex-biopharmaceutical employees convicted in U.S. of insider trading Reuters
Jul-02-18 04:15PM  Merrimack Secures $25 Million Debt Facility with Hercules Capital PR Newswire
Jun-27-18 08:12AM  Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod Zacks +7.26%
Jun-26-18 07:51PM  Ex-Akebia employee jailed for night as insider trading trial starts Reuters
08:12AM  Merrimack Crashes as Phase II Pancreatic Cancer Study Fails Zacks
Jun-25-18 07:55AM  Merrimack to scrap development of pancreatic cancer treatment Reuters -43.83%
07:54AM  UPDATE: Merrimack Pharma shares slide 34% after trial of pancreatic cancer treatment fails to meet main goals MarketWatch
07:29AM  Merrimack to scrap development of pancreatic cancer treatment Reuters
07:20AM  Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer PR Newswire
Jun-15-18 08:41AM  Options Traders Expect Huge Moves in Merrimack Pharmaceuticals (MACK) Stock Zacks
Jun-07-18 09:15AM  Why is Merrimack (MACK) Up 6.3% Since Its Last Earnings Report? Zacks
Jun-04-18 01:57PM  Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-29-18 08:15AM  Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience, Merrimack Pharmaceuticals, and Energizer with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting PR Newswire
May-09-18 10:49AM  Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 Zacks
May-08-18 06:25AM  Merrimack Reports First Quarter 2018 Financial Results PR Newswire
May-03-18 10:13AM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
May-01-18 07:00AM  Merrimack Announces Timing of First Quarter 2018 Investor Conference Call PR Newswire
Apr-09-18 07:30AM  Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Apr-04-18 08:15AM  Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail Fundamental Analysis, Key Performance Indications GlobeNewswire +5.74%
Mar-14-18 07:30AM  Wired News Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer ACCESSWIRE
Mar-13-18 09:45AM  Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 Zacks
Mar-12-18 07:06PM  Edited Transcript of MACK earnings conference call or presentation 12-Mar-18 12:30pm GMT Thomson Reuters StreetEvents -10.28%
07:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:27AM  Merrimack Provides Business Update and Reports 2017 Financial Results PR Newswire
06:25AM  Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer PR Newswire
Mar-05-18 07:00AM  Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference PR Newswire
Feb-27-18 05:11AM  Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Incs (NASDAQ:MACK)? Simply Wall St.
Feb-26-18 06:55AM  Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer PR Newswire
Feb-23-18 09:10AM  What's in the Cards for Merrimack (MACK) in Q4 Earnings? Zacks
Feb-20-18 07:00AM  Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology PR Newswire
Feb-15-18 07:00AM  Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference PR Newswire
Feb-06-18 08:25AM  New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-04-18 08:00AM  Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-11-17 04:12AM  Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound? Zacks
Nov-30-17 06:50AM  Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors PR Newswire
Nov-20-17 08:04PM  With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Incs (MACK) Management Done A Good Job? Simply Wall St.
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 08:31PM  Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
Nov-08-17 10:15AM  Merrimack beats 3Q profit forecasts Associated Press
08:25AM  Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss Zacks
06:40AM  Merrimack Reports Third Quarter 2017 Financial Results PR Newswire
06:30AM  Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-17 10:17AM  What's in the Cards for Merrimack (MACK) in Q3 Earnings? Zacks
Nov-01-17 07:10AM  Featured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer ACCESSWIRE
06:55AM  Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call PR Newswire
Oct-30-17 09:45AM  Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121 SmarterAnalyst
09:32AM  NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers TheStreet.com
06:55AM  Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer PR Newswire
Oct-28-17 10:41AM  Have Investors Already Priced In Merrimack Pharmaceuticals Incs (MACK) Growth? Simply Wall St.
Oct-13-17 07:30AM  Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020 PR Newswire
Oct-10-17 09:21PM  Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio? Simply Wall St.
04:23PM  Merrimack Announces Settlement of Convertible Note Litigation PR Newswire
Sep-20-17 04:15PM  Is It Time To Buy Merrimack Pharmaceuticals Inc (MACK)? Simply Wall St.
Sep-07-17 08:00AM  Today's Research Reports on Trending Tickers: American Superconductor and Merrimack Pharmaceuticals ACCESSWIRE +8.74%
Aug-31-17 09:39AM  Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers TheStreet.com
08:00AM  Merrimack Announces Date of One-for-Ten Reverse Stock Split PR Newswire
Aug-14-17 06:55AM  Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer PR Newswire
Aug-13-17 01:35AM  Edited Transcript of MACK earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 10:16AM  Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls Zacks
Aug-09-17 10:59PM  Merrimack misses 2Q profit forecasts Associated Press
07:23AM  Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss Zacks
06:55AM  Merrimack Reports Second Quarter 2017 Financial Results PR Newswire
06:10AM  Investor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-17 07:00AM  Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call PR Newswire
Aug-01-17 04:52PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : August 1, 2017 Capital Cube
Jul-28-17 11:18AM  What's in the Cards for Merrimack (MACK) in Q2 Earnings? Zacks
Jul-24-17 06:55AM  Merrimack Appoints Thomas Needham as Chief Business Officer PR Newswire
Jun-27-17 09:51AM  Edited Transcript of MACK earnings conference call or presentation 1-Mar-17 1:30pm GMT Thomson Reuters StreetEvents
Jun-22-17 08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Moleculin Biotech and Merrimack Pharmaceuticals Accesswire +11.45%
Jun-21-17 03:43PM  These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Motley Fool
Jun-20-17 10:33AM  Merrimack Completes Enrollment in Phase II Study for MM-141 Zacks +6.72%
Jun-19-17 06:55AM  Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 PR Newswire
Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.